What is the other name for Wegovy — and why it matters which one you mean

The misconception worth clearing up first: Ozempic is not a weight-loss medicine

Ask ten people what Wegovy's other name is and a good number will say Ozempic. That's understandable, both are semaglutide injections made by Novo Nordisk, and press coverage has used the names interchangeably for years. The reality is simpler and more important than most headlines suggest: in the UK, Ozempic holds a licence for type 2 diabetes, and Wegovy holds one for weight management. Same active ingredient; different licensed indications; different dose ranges; different regulatory standing for each use.

This matters practically. A prescriber issuing Ozempic for weight loss would be doing so off-label. The NHS patient information for semaglutide covers both medicines and sets out their distinct approved uses clearly. For anyone exploring weight management specifically, Wegovy is the product to discuss with a clinician, not Ozempic.

There's a gentle irony here: the confusion has partly driven demand, but it's also pushed people toward sources that sell semaglutide without a prescription, which carries real clinical risk. If you're still unsure whether there is another name for Wegovy that applies to what you've been reading about, it's worth getting that cleared up before you go any further. The name matters because the licence matters.

Every semaglutide brand in the UK, and what each one is actually for

Four brand names sit under the semaglutide umbrella in the UK right now. Wegovy injection (0.25 mg up to 2.4 mg weekly, with the higher 7.2 mg dose approved by the MHRA in April 2026 for adults with a BMI of 30 or above) is licensed for weight management. Ozempic (0.5 mg, 1 mg, 2 mg weekly) is licensed for type 2 diabetes and cardiovascular risk reduction in eligible adults. Rybelsus (3 mg, 7 mg, 14 mg daily tablets) also covers type 2 diabetes. And from June 2026, Wegovy tablets (a once-daily oral formulation titrated from 1.5 mg to a 25 mg maintenance dose) became the first oral GLP-1 medicine licensed in the UK for weight loss.

The NICE technology appraisal for Wegovy (TA875) is clear that the recommendation applies to the injection, used within a specialist weight management service for a maximum of two years. The tablet has only just received MHRA approval; a NICE appraisal would be needed before NHS funding follows. For now, both Wegovy presentations are available privately through regulated pharmacies following clinical assessment.

If you want to read about how the injection and the newer tablet compare on outcomes, our Wegovy overview covers both presentations side by side.

Wegovy's generic name (and when 'semaglutide' is the more useful word to use

Semaglutide is the International Non-proprietary Name (INN)) the generic, chemist's name for the drug. Brand names like Wegovy are marketing designations that attach to a specific product, dose presentation, licensed indication and manufacturer.

Knowing the INN matters in a few practical situations. If you're transferring your prescription between providers, the generic name is what a pharmacist checks on your records. If you're reading a clinical trial (the STEP 1 study published in the New England Journal of Medicine, for instance, reported roughly 15 % average weight reduction over 68 weeks with semaglutide 2.4 mg in adults without diabetes) the paper will refer to semaglutide throughout, not to the brand. And when MHRA drug safety communications go out, they name the active ingredient first.

So: Wegovy is the brand, semaglutide is the drug, and understanding what another name for Wegovy actually refers to depends entirely on which product and which licence is in play. For a fuller picture of the names this question comes in, our guide to all the names for Wegovy takes each one in turn.

How this affects choosing a weight-loss treatment in the UK

Wegovy (semaglutide injection or tablet) is one of two GLP-1 class medicines currently licensed for weight management in the UK. The other is Mounjaro (tirzepatide), which acts on both the GIP and GLP-1 receptors, a different mechanism. If you're weighing up the two, the practical differences in results, side-effect profiles and eligibility thresholds are worth understanding before any consultation. Our Wegovy and Ozempic comparison unpicks the semaglutide products specifically, while our treatment overview maps out all the options licensed for weight management.

Cost is a reasonable thing to think about at this point too. Wegovy's pricing has changed over the past year, and understanding what a legitimate private prescription actually covers is useful before you start comparing numbers. You'll find that context on our Wegovy pricing page.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers the same day. Once clinically approved, treatment is dispatched the same day for free next-working-day delivery. If you'd like a prescriber to assess which treatment suits your situation, the right place to begin is a free consultation with our clinical team.

You can read more about how we work, or speak to our prescribers to get started.